Quick Answer
IN8BIO, INC. reported Net Income of -$19.44 million for fiscal year 2025.
IN8BIO, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$19.44M +36.1% |
-$30.44M -1.4% |
-$30.01M -5.2% |
-$28.52M -94.6% |
-$14.65M -71.2% |
-$8.56M |
| Diluted EPS | -$4.44 +74.0% |
-$17.05 -1605.0% |
-$1.00 +26.5% |
-$1.36 +7.5% |
-$1.47 | — |
| Total Assets | $32.28M +54.1% |
$20.94M -37.9% |
$33.71M +2.0% |
$33.04M -21.8% |
$42.22M +101.9% |
$20.91M |
| Stockholders Equity | $27.56M +90.3% |
$14.48M -41.9% |
$24.94M +9.7% |
$22.73M +159.5% |
-$38.18M -130.3% |
-$16.58M -79.4% |
| R&D Expense | $10.21M -39.8% |
$16.96M +0.8% |
$16.83M +19.7% |
$14.06M +91.4% |
$7.35M +36.6% |
$5.38M |
| Operating Income | -$19.44M +36.1% |
-$30.44M -1.4% |
-$30.01M -5.2% |
-$28.52M -94.6% |
-$14.65M -71.2% |
-$8.56M |
| Shares Outstanding | 9.77M +304.2% |
2.42M -94.4% |
43.29M +76.4% |
24.55M +30.7% |
18.78M +398.9% |
3.76M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.85M | +45.6% | +24.3% |
| Diluted EPS | September 30, 2025 | -$0.85 | +81.1% | +31.5% |
| Total Assets | September 30, 2025 | $16.77M | +5.0% | -13.4% |
| Stockholders Equity | September 30, 2025 | $13.19M | +53.6% | -13.5% |
| R&D Expense | September 30, 2025 | $2.10M | -36.4% | -15.4% |
| Operating Income | September 30, 2025 | -$3.85M | +45.6% | +24.3% |
| Shares Outstanding | September 30, 2025 | 4.59M | -90.2% | +12.5% |
- IN8BIO, INC. reported Net Income of -$19.44 million for fiscal year 2025.
- IN8BIO, INC. showed an increase of +36.1% in Net Income compared to the prior fiscal year.
- IN8BIO, INC. reported Diluted EPS of $4.44 per share (loss) for fiscal year 2025.
- IN8BIO, INC. showed an increase of +74.0% in Diluted EPS compared to the prior fiscal year.
- IN8BIO, INC. reported Total Assets of $32.28 million for fiscal year 2025.
- IN8BIO, INC. showed an increase of +54.1% in Total Assets compared to the prior fiscal year.
- IN8BIO, INC. reported Stockholders Equity of $27.56 million for fiscal year 2025.
- IN8BIO, INC. showed an increase of +90.3% in Stockholders Equity compared to the prior fiscal year.
- IN8BIO, INC. reported R&D Expense of $10.21 million for fiscal year 2025.
- IN8BIO, INC. showed a decrease of -39.8% in R&D Expense compared to the prior fiscal year.
- IN8BIO, INC. reported Operating Income of -$19.44 million for fiscal year 2025.
- IN8BIO, INC. showed an increase of +36.1% in Operating Income compared to the prior fiscal year.
- IN8BIO, INC. reported Shares Outstanding of 9.77 million shares for fiscal year 2025.
- IN8BIO, INC. showed an increase of +304.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: